Lyell Immunopharma Inc. has issued 625,000 shares of its common stock to the securityholders of ImmPACT Bio USA Inc. following the achievement of certain clinical milestones. The transaction was conducted under a private placement and was exempt from registration under the Securities Act. The document does not provide the price of these shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.